A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors

Summary

It is a single-arm, open-label, multicenter, phase II study to evaluate the safety, efficacy, pharmacokinetics (PK) and immunogenicity of AK104 as a single agent in subjects with previously-treated locally advanced unresectable or metastatic MSI-H or dMMR solid tumors.

Timeline

Start

2020-04-24

Primary completion

2022-09-30

Completion

2022-09-30

Outcome

Outcome not reported

Stopped: “Due to difficuty of erollment and consideration of clinical guideline,The sponsor decided to stop study.”

Drugs

Indications